Identification of "sarsasapogenin-aglyconed" timosaponins as novel Aβ-lowering modulators of amyloid precursor protein processing

Chemical Science
Lai-King SyChi-Ming Che

Abstract

The inhibition of amyloid β (Aβ) peptide production is a key approach in the development of therapeutics for the treatment of Alzheimer's disease (AD). We have identified that timosaponins consisting of sarsasapogenin (SSG) as the aglycone can effectively lower the production of Aβ peptides and stimulate neurite outgrowth in neuronal cell cultures. Structure-activity relationship studies revealed that the cis-fused AB ring, 3β-configuration, spiroketal F-ring and 25S-configuration of SSG are the essential structural features responsible for the Aβ-lowering effects and neurite-stimulatory activity. New synthetic derivatives that retain the SSG scaffold also exhibited an Aβ lowering effect. Treatment of cells with timosaponins led to modulation of amyloid precursor protein (APP) processing through the suppression of β-cleavage and preferential lowering of the production of the 42-amino acid Aβ species (Aβ42) without affecting another γ-secretase substrate. The SSG and "SSG-aglyconed" timosaponins also penetrated brain tissue and lowered brain Aβ42 levels in mice. Our studies demonstrate that timosaponins represent a unique class of steroidal saponins that may be useful for the development of AD therapeutics.

References

Sep 6, 2002·Journal of Alzheimer's Disease : JAD·D H SmallV Nurcombe
Mar 18, 2003·Bioorganic & Medicinal Chemistry Letters·Thomas FichertJohn R Proudfoot
Sep 24, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kavon Rezai-ZadehJun Tan
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Apr 26, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Feng ChenChristopher B Eckman
Dec 5, 2006·Phytochemistry·Jean-Paul VinckenHarry Gruppen
Dec 16, 2006·Current Opinion in Pharmacology·Johan Lundkvist, Jan Näslund
Jun 13, 2008·Nature·Thomas L KukarTodd E Golde
Aug 22, 2009·European Journal of Pharmacology·Jinyoung HurSun Yeou Kim
Jan 19, 2010·The Journal of Biological Chemistry·Valérie VingtdeuxPhilippe Marambaud
Mar 5, 2011·Lancet·Clive BallardEmma Jones
Apr 5, 2011·Annual Review of Neuroscience·Richard J O'Brien, Philip C Wong
Apr 15, 2011·Bioorganic & Medicinal Chemistry Letters·Sunil Kumar UpadhyayDonna M Neumann
Jul 16, 2011·The Journal of Biological Chemistry·Chun-Nam LokChi-Ming Che
Jul 28, 2011·Journal of Microbiology and Biotechnology·Hongjun HuYexin Ouyang
Nov 30, 2011·Journal of Neurochemistry·Arun K GhoshJordan Tang
Feb 22, 2012·Neurochemical Research·Massimo AureliSandro Sonnino
Jul 31, 2012·Advances in Pharmacology·Michael S Wolfe
May 30, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Joo In JungKevin M Felsenstein
Oct 11, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Verena K BurgMarcus O W Grimm

❮ Previous
Next ❯

Citations

Feb 26, 2019·Frontiers in Cellular Neuroscience·Xuan HeYongfang Zhang
Aug 3, 2017·Journal of the American Society for Mass Spectrometry·Wei ZhengBaiping Ma
Aug 2, 2021·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Yu-Meng ZhangYao-Wu Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
fluorescence microscopy
NMR

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.